Oritavancin (ORI) is a semisynthetic lipoglycopeptide with bactericidal activity against Gram-positive bacteria including Methicillin-resistant Staphylococcus aureus (MRSA). The purpose of this study to evaluates the efficacy and safety of ORI in patients with ABSSSI and assess the potential sustained clinical response up to 90 days after single dose ORI therapy.
Retrospective chart review of all patients that received ORI in the hospital-owned infusion clinic of a large community hospital (2/2015 – 11/2016). Adult patients included who received one dose of ORI, and had adequate follow-up information for evaluation. Data collected includes: demographics, culture results, adverse events, and readmission rates at 30, 60 and 90 days after ORI dose.
A total of 67 patients met the inclusion criteria for evaluation. Age range 26-96 y, 43 % males, 84 % Caucasian and 15 % African American. ORI was primarily used to treat cellulitis (79%) followed by abscess (21%). Prior to ORI infusion, patients were predominately located in the inpatient setting (69%) followed by outpatient (19%), and emergency department (12%). The utilization of ORI resulted in the avoidance of an inpatient admission as well as the facilitation of discharge from the hospital. The primary sites of infections are lower extremity (70%), abdomen (12%), upper extremity (6%), face (6%), and other (6%). A total of 39 patients had evaluable microbiology data. The most common organism was Staphylococcus aureus 41% (35% MRSA). A total of 6 (9%), 3 (4%), and 2 (3%) patients were readmitted within 30, 60, and 90 days of ORI therapy with diagnosis of recurrent ABSSSI, respectively. No patients admitted twice in 90 days’ period. Mean hospital length of stay was 4.1 days (range 1-9). ORI was relatively well tolerated with 2 patients (3%) experiencing an adverse event during the infusion included: shortness of breath, rash, and chest pain that ultimately required discontinuation of ORI infusion.
ORI single-dose regimen is an effective therapy for ABSSI that ensures compliance with low rate of readmissions at 30, 60, and 90 days and relatively low incidence of adverse events. Further studies needed to confirm the additional protective benefits of ORI for the treatment and prevention of ABSSSI.
A. Hassoun, None
See more of: Poster Abstract Session